Investment Q&A

Q: Asked by Doris on January 09, 2023
5I RESEARCH ANSWER:
We are not big fans of the staples sector overall right now in the US. It has fared decently over the last year but valuations are at the higher end now, as growth should moderate alongside inflation. Also, now that bonds offer more attractive yields, we think the relative attractiveness of staples is lower than it was a year ago (more safe alternatives for stability and yield now).

We think it is difficult to be too hard on COST though. Overall, we think staples names in Canada look a bit more attractive due to what looks like lower valuations on average. In Canada, we think PBH, ATD and NWC are worth looking at.

this is an answer you gave regarding staples . would you feel the same eay about hwalthcare stocks, such as gilead, etc

Q: what is your feeling on Medtronic now? If I buy it in a US RRSP is there still a whitholding tax?

Q: Both have had a good run but I just own Starbucks. I'm considering swapping it for TJX. What do you think?

Q: What is going on with Enphase stock? It has gone almost straight down since mid-december. It's last quarter looked quite good. Is it worries over the next quarter?

Q: I'm wondering about the big drop in JNJ today?

Q: It's time to add to my TFSA. I own ADBE, GOOG, AAPL, NVDA, PYPL, QCOM, CRM and TOL in this account, where longterm growth is the investment objective. Should any of these be switched? Please recommend replacements if so and ignore sector/market cap considerations. I wish to add to either NVDA or PYPL, which of these should I add to? Deduct as many credits as required. Thanks, and wishing you all the best for 2023.

Q: Peter; Does the Broadcom deal impact other chip companies, like NVDA? Is it a “ big”: deal in the chip market? Thanks
Rod

Q: I'm looking at your answer to Shane's Jan 5 question about your caveats on recovery of stocks. Do you see any of the stocks listed here whose recovery may be limited and if so, which ones and based on which caveats? Thank you.

Q: I thought that I had asked this question before, but I went through 6 web pages of "My Questions" and came up empty.

What would you say is the "most" CSU-like stock in the US? Thanks again!

Q: I just wanted to circle back to one of my last questions around META to confirm something. I had a typo in my question where I said $425M shares but had the dollar sign accidentally, making it seem like the buyback was $425M dollars in shares, but in fact its 425M shares, which is obviously WAY more of a spend. You mentioned that there would be no dilution since their recent buybacks outweigh the new share increase. But with the correction mentioned above I believe it would put the 2023 share count a fair bit higher than the 2022 and 2021, which hasn't happened for a number of years for FB since they've been lowering the share count since 2018. Does this add up, and is META in fact diluting a fair bit with this move? Thx. I see 2020: 2,851B
2021: 2,815B
2022: Not sure
2023: With addition of 425M shares, somewhere above 3B

Q: I'm wanting to increase my holdings in US healthcare. For share price appreciation and safety, which would you prefer and why?

Q: Hi,
Of this list do any of these names have concerns and if so, what might they be? Are there any you would wish to wait longer before buying? Any you do not think appropriate buys in this market? Others you feel are more compelling? If you were to buy these, in what order would you do so? I know - lots of questions - feel free to deduct accordingly! My preference is for stability of future earnings, lower or no debt and the dividend is a bit of a bonus, but not something to rely on. Many thanks!
Dawn

Q: Hi 5i happy new year! I believe its time to step into US perpetual preferred shares due to interest rates. I'm having problems finding these and I'm hoping you can help. Quality needs to be high to the highest as this is for my retirement. I am an advocate of diversification so please if you can have a few stable sectors listed, thanks!

Q: I noticed that your position on Google has changed in the past couple of months. Previously, you were always recommending it as #1 stock for growth/risk combination, lately I don't see this recommendation anymore. At the moment, it is the worst performing stock in my portfolio and I am down over USD $20K on it. Unfortunately, it's in TFSA portfolio, so I cannot sell and claim cap loss. Do you still believe in bright future for Google considering the challenges (e.g. Microsoft combining efforts with Open AI to integrate chatGPT in Bing and challenge Google search dominance and, by proxy, ad revenue)? Considering that the stock is held in TFSA, would you keep it or sell and replace with something else? If you recommend selling, please list your suggestions. What is your current recommendation on the US market for better growth/risk equilibrium? Thanks!

Q: Do you know the reason for the huge drop in TMO today? Please comment on your overall thoughts on this company. Thank You.

Q: I asked about SIMO in July, but wonder your thoughts now. The price looks good for a sale.

Q: You haven't had a look at this company in a few years. Could I get an updated view on them, please? Has their debt gone down?

Q: I've owned this company for 2+ years in a registered account and I'm significantly underwater.
In your analysis would you sell but stay in the security business with another company?

Thank you

Q: Happy New Year to all at 5i.

It's time to once again figure out how to invest this year's TFSA contribution in my growth orientated portfolio. Like most Canadians, I probably have quite a home country bias so I thought for 2023 I would look at US companies available through CDRs to avoid currency conversion expenses. (I do already own GOOGL, CRWD & PINS). I wonder if you can suggest 3 or 4 USA growth companies that are available as CDRs.
Thanks
David

Q: Good day,
I own NVDA, which is down quite a bite, as is the case with all tech stocks. However, I came across this report in Entrepeneur which I thought was worrisome. Now, I know nothing about this magazine. I'm wondering if you might comment on it. I noted that you did answer a question on November 23 that partially addressed these issues.

"For the fiscal 2023 third quarter ended October 30, 2022, NVDA’s revenue declined 16.5% year-over-year to $5.93 billion, and its gross profit fell 31.4% year-over-year to $3.18 billion. Its total operating expenses increased 31.4% from the year-ago value to $2.58 billion, while its non-GAAP operating income declined 54.6% year-over-year to $1.54 billion.

In addition, NVDA’s non-GAAP net income and non-GAAP EPS decreased 51% and 50.4% from the previous year’s quarter to $1.46 billion and $0.58, respectively.

In terms of forward EV/Sales, NVDA is currently trading at 13.43x, 420.8% higher than the industry average of 2.58x. Its forward EV/EBITDA multiple of 58.10 is 364.6% higher than the industry average of 12.51. In addition, its forward Price/Sales ratio of 13.47 is 429.4% higher than the industry average of 2.54.

Analysts expect NVDA’s EPS to decline 39.3% year-over-year to $0.80 for the fourth quarter (ending January 2023). Its revenue estimate of $6.02 billion for the current quarter is expected to decline 21.2% year-over-year."

Thank you for all your excellent work.